Nasal Nitric Oxide is a Marker of Poor Asthma Control
Overview
Authors
Affiliations
Asthma control, evaluated by symptoms, exacerbations rate and lung function may be greatly influenced by comorbidities, particularly chronic rhinosinusitis (CRS). Measurement of nasal nitric oxide (nNO) is a simple way to assess the severity of CRS. We aimed to analyze the relationship between asthma control and nasal NO. All patients with moderate-to-severe asthma on regular follow-up at our Outpatients' Clinic between November 2009 and April 2010 were included into the study. All patients were evaluated for asthma control by asthma control questionnaire (ACQ) and comorbidities (rhinitis, chronic rhinosinusitis with (CRSwNP) or without nasal polyps, obesity). Exhaled nitric oxide and nNO were obtained in all patients. Eighty-two patients were enrolled (mean age: 48 years, range: 21-80; 42 females). According to ACQ, 53 patients (64.6%) reported controlled asthma. Patients with uncontrolled asthma had lower nNO and higher prevalence of CRSwNP, with a significant correlation between nNO and ACQ. nNO is a biomarker negatively related to asthma control. As low nNO values were associated to CRSwNP, our results indicate that asthma control is highly influenced by this comorbidity.
Update on the Role of FeNO in Asthma Management.
Murugesan N, Saxena D, Dileep A, Adrish M, Hanania N Diagnostics (Basel). 2023; 13(8).
PMID: 37189529 PMC: 10137365. DOI: 10.3390/diagnostics13081428.
Heffler E, Saccheri F, Bartezaghi M, Canonica G Clin Transl Allergy. 2020; 10:25.
PMID: 32607141 PMC: 7318524. DOI: 10.1186/s13601-020-00330-1.
Heffler E, Carpagnano G, Favero E, Guida G, Maniscalco M, Motta A Multidiscip Respir Med. 2020; 15(1):36.
PMID: 32269772 PMC: 7137762. DOI: 10.4081/mrm.2020.36.
Ambrosino P, Molino A, Spedicato G, Parrella P, Formisano R, Motta A J Clin Med. 2020; 9(1).
PMID: 31940834 PMC: 7020063. DOI: 10.3390/jcm9010200.
The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma.
Marone G, Granata F, Pucino V, Pecoraro A, Heffler E, Loffredo S Front Pharmacol. 2019; 10:1387.
PMID: 31866859 PMC: 6908970. DOI: 10.3389/fphar.2019.01387.